Teglbjaerg L L, Mathiesen L R, Søeberg B, Nielsen L, Thorsen B, Buhl M, Pedersen C, Bonnevie O, Nielsen C, Vestergaard B F
Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark.
Scand J Infect Dis. 1989;21(4):367-73. doi: 10.3109/00365548909167439.
In 1987, a total of 138 Danish patients (94 AIDS and 44 ARC) received treatment with zidovudine, a total observation period of 572 treatment months. 15 AIDS and 1 ARC patient died after a median of 70 days (range 2-295). In the ARC group 4 patients developed AIDS (3 Pneumocystis carinii pneumonia, 1 Kaposi's sarcoma). Among the AIDS patients 38 new opportunistic infections were reported. 24 of these opportunistic infections occurred within 6 weeks after treatment initiation. 79 patients were observed for more than 3 months, 25 of these had their daily dose zidovudine reduced, usually from 1,200 mg to 600 mg, 9 others were temporarily off drug. HIV antigen was analyzed in serum samples from 93 patients. Of these, 28 (52%) of 54 initially HIV antigen-positive became antigen-negative, 7 (18%) of 39 initially HIV antigen-negative became antigen-positive within the first 8 weeks of zidovudine treatment. In 57 patients the total count of CD4+ cells were evaluated. A significant increase in the number of CD4+ cells was observed during treatment. In nearly all patients an increase in MCV and a decrease in neutrophil count was observed. 44 of the patients received a total of 307 blood transfusions on 94 occasions and 19 (14%) patients required multiple transfusions. The mortality among the AIDS patients was significantly lower compared to historical controls. In our experience zidovudine treatment is reasonably well tolerated and the side effects are manageable.
1987年，共有138名丹麦患者（94例艾滋病患者和44例艾滋病相关综合征患者）接受了齐多夫定治疗，总观察期为572个治疗月。15例艾滋病患者和1例艾滋病相关综合征患者在中位时间70天后死亡（范围为2 - 295天）。在艾滋病相关综合征组中，有4例患者发展为艾滋病（3例卡氏肺孢子虫肺炎，1例卡波西肉瘤）。在艾滋病患者中，报告了38例新的机会性感染。其中24例机会性感染发生在治疗开始后的6周内。79例患者被观察了3个多月，其中25例患者的齐多夫定日剂量减少，通常从1200毫克减至600毫克，另外9例患者暂时停药。对93例患者的血清样本进行了HIV抗原分析。其中，54例最初HIV抗原阳性的患者中有28例（52%）变为抗原阴性，39例最初HIV抗原阴性的患者中有7例（18%）在齐多夫定治疗的前8周内变为抗原阳性。对57例患者的CD4 + 细胞总数进行了评估。治疗期间观察到CD4 + 细胞数量显著增加。几乎所有患者均观察到平均红细胞体积增加和中性粒细胞计数减少。44例患者共接受了94次输血，其中19例（14%）患者需要多次输血。与历史对照组相比，艾滋病患者的死亡率显著降低。根据我们的经验，齐多夫定治疗的耐受性相当良好，副作用是可控的。
